NDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Mechanism of Action
gamma-aminobutyric acid-A (GABA A ) receptors in the brain and enhances GABA-mediated synaptic inhibition.
Pharmacologic Class:
Benzodiazepine
Clinical Trials (5)
Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects
Started Jan 2014
8 enrolled
Healthy
A Study of the Effect of LY2216684 on Lorazepam
Started Dec 2010
28 enrolled
Major Depressive Disorder
Seizure Therapy With Intravenous Levetiracetam and Lorazepam
Started Jan 2008
0Seizures
GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)
Started Nov 2002
38 enrolled
Anxiety Disorder
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
Started Jun 2001
226 enrolled
SchizophreniaPsychotic DisordersEmergency Treatment
Loss of Exclusivity
LOE Date
Jan 8, 2034
95 months away
Patent Expiry
Jan 8, 2034
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8999393 | Jan 8, 2034 | Product | U-3210 |